Xilio Therapeutics
30 hedge funds and large institutions have $33.5M invested in Xilio Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.66% less ownership
Funds ownership: 58.25% → 57.59% (-0.66%)
6% less funds holding
Funds holding: 32 → 30 (-2)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
94% less capital inflows, than outflows
Capital inflows: $24.5K | Capital outflows: $401K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$22.8K |
| 2 |
Renaissance Technologies
New York
|
+$1.08K |
| 3 |
Cullen/Frost Bankers
San Antonio,
Texas
|
+$261 |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$261 |
| 5 |
JP Morgan Chase
New York
|
+$37 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Octagon Capital Advisors
New York
|
-$284K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$34.4K |
| 3 |
Millennium Management
New York
|
-$33.8K |
| 4 |
NWAM LLC
Mercer Island,
Washington
|
-$26.2K |
| 5 |
Laurion Capital Management
New York
|
-$9.7K |
XLO Hedge Fund Activity: Q3 2023 in Review
30 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q3 2023, worth a combined $33.5M — down 20% from $41.9M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of XLO and 1 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $22.8K. The largest seller was Octagon Capital Advisors, cutting an estimated $284K.
- 30 institutional investors held Xilio Therapeutics (XLO) as of Q3 2023, down from 32 in Q2 2023.
- Funds reported $33.5M of Xilio Therapeutics stock for Q3 2023, down 20% quarter-over-quarter.
- 1 fund opened new Xilio Therapeutics positions in Q3 2023 and 3 closed out, a net change of -2 holders.
- The largest Xilio Therapeutics buyer in Q3 2023 was Dimensional Fund Advisors, an estimated $22.8K added.
- The largest Xilio Therapeutics seller in Q3 2023 was Octagon Capital Advisors, an estimated $284K sold.
Based on aggregated 13F filings for Q3 2023.